RxDoctor Payments Data

James Barna, MD

Otolaryngology · Clearwater, FLNPI 1831249861

Payments from drug & device makers

$1,565in general payments, 2019–2025

Across 27 payments — averaging $57.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$746
  • Neurent Medical Limited$169
  • Optinose US, Inc.$119
  • Intersect ENT, Inc.$106
  • Acclarent, Inc$90
  • Inspire Medical Systems, Inc.$78
  • plus $257 from 7 others

What the payments were for

  • Travel & lodging$64641%
  • Food & beverage$91558%
  • Gifts$40%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,565 in reported general payments places this provider in the 45th percentile of 586 otolaryngology providers in Florida.

See all otolaryngology providers in Florida

Medicare billing

Part B allowed, 2024
$194,544
Medicare patients
687
Services billed
3,860

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab17$75,048
XhanceFluticasone Propionate16$10,893
Ipratropium Bromide269$8,219
Epinephrine25$4,247
Azelastine Hcl155$3,911
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth36$3,413
Dexlansoprazole DrDexlansoprazole17$2,165
Fluocinolone Acetonide Oil36$1,476
Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort22$1,180
Omeprazole77$1,116
Montelukast Sodium30$407
Fluticasone Propionate38$353
Ofloxacin17$326
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav19$256
Mupirocin31$224

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Optinose US, Inc.Xhance$119$10,89316 claims
Hikma Pharmaceuticals USAEpinephrine$19$4,24725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 586 otolaryngology providers in Florida.

Other otolaryngology in Clearwater

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →